Assessment of cognitive function of the elderly population

Effects of darifenacin

Richard B. Lipton, Ken Kolodner, Keith Wesnes

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Purpose: Overactive bladder is common in the elderly population, which is susceptible to cognitive disorders and drug induced cognitive impairment. Existing overactive bladder treatments may cause adverse events, such as cognitive impairment, due to antagonism of the M1 receptor in the central nervous system. In this study we evaluated the effect of darifenacin, an M3 selective antagonist, on cognitive function in elderly volunteers without clinical dementia. Materials and Methods: This double-blind, 3-period crossover study randomized 129 volunteers 65 years or older with no/mild cognitive impairment to receive 3 of 5 treatments, namely darifenacin controlled release (3.75, 7.5 or 15 mg once daily), darifenacin immediate-release (5 mg 3 times daily) or matching placebo for 14 days. Each treatment period was separated by 7 days of washout. Cognitive function tests were completed at baseline and at treatment end. Results: For the primary end points of memory scanning sensitivity, speed of choice reaction time and word recognition sensitivity, there were no statistically significant differences for darifenacin vs placebo. There were no statistically significant differences in secondary variables except memory scanning speed, which increased in all groups relative to baseline, but improvement was greater with placebo than with 3.75 mg darifenacin. Darifenacin treatment was not associated with changes in alertness, contentment or calmness, which are likely to be clinically relevant. Darifenacin was well tolerated. Conclusions: In elderly volunteers 2 weeks of treatment with darifenacin had no effect on cognitive function compared with baseline and it was not significantly different from placebo. This may be related to its M3 receptor selectivity with negligible M1 receptor antagonism.

Original languageEnglish (US)
Pages (from-to)493-498
Number of pages6
JournalJournal of Urology
Volume173
Issue number2
DOIs
StatePublished - Feb 2005

Fingerprint

Cognition
Population
Placebos
Volunteers
Overactive Urinary Bladder
Therapeutics
darifenacin
Double-Blind Method
Cross-Over Studies
Reaction Time
Dementia
Central Nervous System
Pharmaceutical Preparations
Cognitive Dysfunction

Keywords

  • Aged
  • Bladder
  • Darifenacin
  • Neurobehavioral manifestations
  • Receptors, muscarinic

ASJC Scopus subject areas

  • Urology

Cite this

Assessment of cognitive function of the elderly population : Effects of darifenacin. / Lipton, Richard B.; Kolodner, Ken; Wesnes, Keith.

In: Journal of Urology, Vol. 173, No. 2, 02.2005, p. 493-498.

Research output: Contribution to journalArticle

Lipton, Richard B. ; Kolodner, Ken ; Wesnes, Keith. / Assessment of cognitive function of the elderly population : Effects of darifenacin. In: Journal of Urology. 2005 ; Vol. 173, No. 2. pp. 493-498.
@article{d251d908a35842348eb4360ed3ccdf10,
title = "Assessment of cognitive function of the elderly population: Effects of darifenacin",
abstract = "Purpose: Overactive bladder is common in the elderly population, which is susceptible to cognitive disorders and drug induced cognitive impairment. Existing overactive bladder treatments may cause adverse events, such as cognitive impairment, due to antagonism of the M1 receptor in the central nervous system. In this study we evaluated the effect of darifenacin, an M3 selective antagonist, on cognitive function in elderly volunteers without clinical dementia. Materials and Methods: This double-blind, 3-period crossover study randomized 129 volunteers 65 years or older with no/mild cognitive impairment to receive 3 of 5 treatments, namely darifenacin controlled release (3.75, 7.5 or 15 mg once daily), darifenacin immediate-release (5 mg 3 times daily) or matching placebo for 14 days. Each treatment period was separated by 7 days of washout. Cognitive function tests were completed at baseline and at treatment end. Results: For the primary end points of memory scanning sensitivity, speed of choice reaction time and word recognition sensitivity, there were no statistically significant differences for darifenacin vs placebo. There were no statistically significant differences in secondary variables except memory scanning speed, which increased in all groups relative to baseline, but improvement was greater with placebo than with 3.75 mg darifenacin. Darifenacin treatment was not associated with changes in alertness, contentment or calmness, which are likely to be clinically relevant. Darifenacin was well tolerated. Conclusions: In elderly volunteers 2 weeks of treatment with darifenacin had no effect on cognitive function compared with baseline and it was not significantly different from placebo. This may be related to its M3 receptor selectivity with negligible M1 receptor antagonism.",
keywords = "Aged, Bladder, Darifenacin, Neurobehavioral manifestations, Receptors, muscarinic",
author = "Lipton, {Richard B.} and Ken Kolodner and Keith Wesnes",
year = "2005",
month = "2",
doi = "10.1097/01.ju.0000148963.21096.5d",
language = "English (US)",
volume = "173",
pages = "493--498",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Assessment of cognitive function of the elderly population

T2 - Effects of darifenacin

AU - Lipton, Richard B.

AU - Kolodner, Ken

AU - Wesnes, Keith

PY - 2005/2

Y1 - 2005/2

N2 - Purpose: Overactive bladder is common in the elderly population, which is susceptible to cognitive disorders and drug induced cognitive impairment. Existing overactive bladder treatments may cause adverse events, such as cognitive impairment, due to antagonism of the M1 receptor in the central nervous system. In this study we evaluated the effect of darifenacin, an M3 selective antagonist, on cognitive function in elderly volunteers without clinical dementia. Materials and Methods: This double-blind, 3-period crossover study randomized 129 volunteers 65 years or older with no/mild cognitive impairment to receive 3 of 5 treatments, namely darifenacin controlled release (3.75, 7.5 or 15 mg once daily), darifenacin immediate-release (5 mg 3 times daily) or matching placebo for 14 days. Each treatment period was separated by 7 days of washout. Cognitive function tests were completed at baseline and at treatment end. Results: For the primary end points of memory scanning sensitivity, speed of choice reaction time and word recognition sensitivity, there were no statistically significant differences for darifenacin vs placebo. There were no statistically significant differences in secondary variables except memory scanning speed, which increased in all groups relative to baseline, but improvement was greater with placebo than with 3.75 mg darifenacin. Darifenacin treatment was not associated with changes in alertness, contentment or calmness, which are likely to be clinically relevant. Darifenacin was well tolerated. Conclusions: In elderly volunteers 2 weeks of treatment with darifenacin had no effect on cognitive function compared with baseline and it was not significantly different from placebo. This may be related to its M3 receptor selectivity with negligible M1 receptor antagonism.

AB - Purpose: Overactive bladder is common in the elderly population, which is susceptible to cognitive disorders and drug induced cognitive impairment. Existing overactive bladder treatments may cause adverse events, such as cognitive impairment, due to antagonism of the M1 receptor in the central nervous system. In this study we evaluated the effect of darifenacin, an M3 selective antagonist, on cognitive function in elderly volunteers without clinical dementia. Materials and Methods: This double-blind, 3-period crossover study randomized 129 volunteers 65 years or older with no/mild cognitive impairment to receive 3 of 5 treatments, namely darifenacin controlled release (3.75, 7.5 or 15 mg once daily), darifenacin immediate-release (5 mg 3 times daily) or matching placebo for 14 days. Each treatment period was separated by 7 days of washout. Cognitive function tests were completed at baseline and at treatment end. Results: For the primary end points of memory scanning sensitivity, speed of choice reaction time and word recognition sensitivity, there were no statistically significant differences for darifenacin vs placebo. There were no statistically significant differences in secondary variables except memory scanning speed, which increased in all groups relative to baseline, but improvement was greater with placebo than with 3.75 mg darifenacin. Darifenacin treatment was not associated with changes in alertness, contentment or calmness, which are likely to be clinically relevant. Darifenacin was well tolerated. Conclusions: In elderly volunteers 2 weeks of treatment with darifenacin had no effect on cognitive function compared with baseline and it was not significantly different from placebo. This may be related to its M3 receptor selectivity with negligible M1 receptor antagonism.

KW - Aged

KW - Bladder

KW - Darifenacin

KW - Neurobehavioral manifestations

KW - Receptors, muscarinic

UR - http://www.scopus.com/inward/record.url?scp=12544253619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12544253619&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000148963.21096.5d

DO - 10.1097/01.ju.0000148963.21096.5d

M3 - Article

VL - 173

SP - 493

EP - 498

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -